Management of Bcr-Abl-positive leukemias with dasatinib

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1529-1536

  Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bcr Abl; Chronic myelogenous leukemia; Dasatinib; Imatinib

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CORTICOSTEROID; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SGX 70430; TANESPIMYCIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; CYTOPENIA; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEART DISEASE; HUMAN; LEUKOPENIA; LUNG EDEMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; SIDE EFFECT; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; VOMITING;

CLINICAL TRIALS AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 37349026929     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1529     Document Type: Article

References (51)

1. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819-830 (2003).
2. Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front. Biosci. 11, 198-208 (2006).
3. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. 108, 180-202 (2002).
4. Redaelli A, Bell C, Casagrande J et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev. Anticancer Ther. 4, 85-96 (2004).
5. Gökbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev. Clin. Erp. Hematol. 6, 114-141 (2002).
6. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 118-122 (2005).
7. Baccarani M, SagliO, G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood 108, 1809-1820 (2006).
8. Hehlmann R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 109, 4686-4692 (2007).
9. Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-AbI inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505 (2005).
10. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin. Hematol. 44, 15-24 (2007).
11. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am. Soc. Hematol. Educ. Program 183-187 (2005).
12. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
13. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood DOI:10.1182/blood-2007-06-093617 (2007).
14. Martinelli G, Rosti G, le Coutre P et al. A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with Philadelphia-positive chronic myelogenous; leukemia in chronic phase. Heamatologica 92(Suppl. 1), 207 (2007).
15. Ottman O, Larson R, Kantarjian H et al. Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia in blast crisis or relapsed/reft-actory-Ph+ acute lymphoblastic leukemia. Haematologica 92 (Suppl. 1), 207 (2007) (Epub ahead of print).
16. le Coutre P, Larson R, Kantarjian H et al. A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase. Haematologica 92(Suppl. 1), 207-208 (2007).
17. Bruemmendorf T, Cortes J, Kantaryan H et al. Bosutinib (SKI-606) exhibits clinical activity in patients with philadelphia chromosome positive CML or ALL who failed imatinib. Haematologica 92(Suppl. 1), 116 (2007).
18. Craig AR, Kantarjian HM, Cortes JE et al. A Phase I study of INNO-406, a dual inhibitor of Ab1 and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J. Clin. Oncol. 25(Suppl. 18), S368 (2007).
19. Gleevec ®, prescribing information. Novartis Pharmaceuticals, NJ, USA (2007)
20. Sprycel® prescribing information. Bristol-Myers Squibb, NY, USA (2007).
21. Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790-5797 (2006).
22. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
23. Fabarius A, Giehl M, Kraemer A et al. Centrosome aberrations, disturbed mitotic spindle formation and G1 arrest in normal and leukemic cells treated with the SRC/ABL inhibitor dasatinib. Blood 108, 614a-615a (2006).
24. Song L, Morris M, Bagui T et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66, 5542-5548 (2006).
25. Taipaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
26. Talpaz M, Kantarjian HM, Paquette R et al. A Phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results from CA180002. J. Clin. Oncol. 23(Suppl. 16 Pt 1) S564-S564 (2005).
27. Hochhaus A, Kantadian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of iniatinib therapy. Blood 109, 2303-2309 (2007).
28. Guilhot F, Apperley J, Facon T et al. Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: updated results of the CA180013 (START-C) trial. Haematologica 92(Suppl. 1), 128 (2007).
29. Guilbot F, Apperiey J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143-4150 (2007).
30. Cortes J, Kim DW, Gullhot F et al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA 180-005 START-A Phase II study. Blood 108, 613a (2006).
31. Cortes J, Rousseiot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109, 3207-3213 (2007).
32. Martinelli G, Hochhaus A, Coutre S et al. Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i). Blood 108, 224a (2006).
33. Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood 110(7), 2309-2315 (2007).
34. Ottmann O, Hochhaus A, Saglio G et al. Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatimb: updated results from CA180015 (START-L) trial. Haematolooca 92 (Suppi. 1), 9-10 (2007).
35. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood 109, 5143-5150 (2007).
36. Quintas-Cardama A, Kantarjian H, O'Brien S et al. Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase. Haematologica 92 (Suppl. 1), 129 (2007).
37. Hochhaus A, Kim DW, Rousselot P et al. Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized Phase-III trial (CA180034). Haematoloogica 92(Suppl. 1), 128-129 (2007).
38. Dombret H, Ottmann OG, Gob Y et al. Dasatinib 140 mg QD vs 70 mg bid in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: results from a randomized, Phase-III trial (CA180035). Haematologica 92 (Suppl. 1), 319 (2007).
39. Mueller MC, Branford S, Radich J et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. Haematologica 92(Suppl. 1), 127 (2007).
40. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat. Rev. Drug Discov. 5, 717-718 (2006).
41. Cortes J, Talpaz M, O'Brien S et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. 11, 3425-3432 (2005).
42. Druker BJ, Guilhot F, O'Brien S, Larson N, on behalf of the IRIS anternational Randomized IF. Long-term benefits of imtinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. Proc. Am. Soc. Clin. Oncol. 24, S338 (2006).
43. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. 120, 990-999 (2003).
44. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 20, 29-41 (2006).
45. Sneed TB, Kantarjian HM, Talpaz M et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100, 116-121 (2004).
46. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18, 1321-1331 (2004).
47. La Rosée P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16, 1213-1219 (2002).
48. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl Acad. Sci. USA 102, 3395-3400 (2005).
49. Mughat TI, Goldman JM. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. Clin. Lymphoma Myeloma 7(Suppl. 2), S81-S84 (2007).
50. Shah NP. Dasatinib. Drugs Today 43, 5-12 (2007).
51. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarjian H. The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targ. Oncol. 1, 186-196 (2006).